Objectives

To evaluate the efficacy of dexamethasone for treatment of primary supratentorial intracerebral hemorrhage, we studied 93 patients 40 to 80 years old, using a double-blind randomized block design. After the subjects were stratified according to their level of consciousness (Glasgow Coma Scale), those with objectively documented primary supratentorial intracerebral hemorrhage were randomly assigned to either dexamethasone or placebo. For ethical reasons, three interim analyses were planned, to permit early termination of the trial if one study group did better than the other. During the third interim analysis, the death rate at the 21st day was identical in the two groups (dexamethasone vs. placebo, 21 of 46 vs. 21 of 47; chi-square = 0.01, P = 0.93). In contrast, the rate of complications (mostly infections and complications of diabetes) was much higher in the dexamethasone group (chi-square = 10.89, P less than 0.001), leading to early termination of the study. In the light of the absence of a demonstrable beneficial effect and the presence of a significant harmful effect, current practices of using dexamethasone for treatment of primary supratentorial hemorrhage should be reconsidered.

Stroke is the third most common cause of death in most western populations after coronary-heart disease and cancer? It is thus the commonest life-threatening neurological disorder, and the resulting disability is the most important single cause of severe disability among western people living in their own homes) The burden of stroke on patients, their families, and society is, correctly, publicised in most developed countries. Stroke in the developing world is less well documented, and some data are not retrievable because of the language barrier or the limited dissemination of data collected. However, more than two-thirds of the world's population live in developing countries, and one of the consensus statements from the Asia-Pacific Consensus Forum on Stroke Management predicts that "In the next 30 years the burden of stroke will grow most in developing countries rather than in developed countries"? Thus stroke in developing countries ought to be examined further--in particular, the similarities and differences in stroke between developed and developing countries.